Q-omics provides the consensus-scored RCSD1 profile across patient tissues and cancer cell-line models. RCSD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RCSD1 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, RCSD1 protein abundance shows 26,379 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, BLCA, and LSCC as cancer lineages where RCSD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RCSD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RCSD1 survival associations across molecular data types. RCSD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RCSD1 RNA expression–survival associations across cancer types. High RCSD1 expression shows unfavorable associations in UVM, but favorable associations in HNSC, UCEC, KIRC, SKCM and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RCSD1 RNA expression.
This table summarizes RCSD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RCSD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RCSD1 shows lower tumor expression in BLCA, COAD, LUAD, LUSC and KICH and higher tumor expression in KIRC. The BLCA box plot shows higher RCSD1 RNA expression in normal versus tumor tissue (log2 FC = −2.350, t-test p < 0.001).
This table shows molecular features associated with RCSD1 in patient tissues and cancer cell lines. In patient samples, RCSD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RCSD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
